Patents Examined by Daniel R Carcanague
  • Patent number: 11512082
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 29, 2022
    Assignee: Proximagen, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • Patent number: 11512075
    Abstract: The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 29, 2022
    Assignee: The Scripps Research Institute
    Inventors: Ryan Shenvi, Jeremy Roach, Yusuke Sasano, Laura Bohn, Cullen Schmid
  • Patent number: 11497751
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: November 15, 2022
    Assignee: Redx Pharma PLC
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E. S. Guisot
  • Patent number: 11498912
    Abstract: Disclosed are methods for performing dynamic nuclear polarization using the polarizing agents described herein. In general, the methods involve (a) providing a frozen sample in a magnetic field, wherein the frozen sample includes a polarizing agent described herein and an analyte with at least one spin half nucleus; (b) polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the polarizing agent; (c) optionally melting the sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the frozen or molten sample. In certain embodiments, the polarizing agents can be peptide-based. In these embodiments, the polarizing agents can be readily prepared by solid-phase peptide synthesis.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 15, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Daniel W. Conroy, Christopher P. Jaroniec
  • Patent number: 11497735
    Abstract: The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 15, 2022
    Assignees: Aurigene Discovery Technologies Limited, Curis, Inc.
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
  • Patent number: 11491117
    Abstract: The disclosure pertains to a compound of formula (I), one of its pharmaceutically acceptable salts, or a composition comprising thereof, for use in the prevention or treatment of glucose intolerance related conditions, insulin deficit related conditions, nonalcoholic fatty liver disease and/or obesity.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 8, 2022
    Assignees: SORBONNE UNIVERSITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, KYOTO UNIVERSITY
    Inventors: Dominique Gauguier, Fumihiko Matsuda, François Brial
  • Patent number: 11484873
    Abstract: Compound of formula 4 or formula 5 wherein L is a neutral ligand, preferably a nitrogen-containing heterocyclic carbene (NHC) such as carbene containing at least two nitrogen atoms, a cyclic aminoalkyl carbene (CAAC) or a bicyclic aminoalkyl carbene (BICAAC); R1, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are, independently, H, unbranched or branched C1-20 alkyl, C5-9 cycloalkyl, unbranched or branched C1-20 alkoxy, optionally bearing one or more halogen atoms, respectively; or aryl, optionally substituted with one or more of unbranched or branched C1-20 alkyl, C5-9 cycloalkyl, unbranched or branched C1-20 alkoxy, aryl, aryloxy, unbranched or branched C1-20 alkylcarbonyl, arylcarbonyl, unbranched or branched C1-20 alkoxycarbonyl, aryloxycarbonyl, heteroaryl, carboxyl, cyano, nitro, amido, aminosulfonyl, N-heteroarylsulfonyl, unbranched or branched C1-20 alkylsulfonyl, arylsulfonyl, unbranched or branched C1-20 alkylsulfinyl, arylsulfinyl, unbranched or branched C1-20 alkylthio, arylthio, sulfonamide, halog
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: November 1, 2022
    Assignee: Verbio Vereinigte BioEnergie AG
    Inventors: Gabor Eros, Georg Emil Frater
  • Patent number: 11485740
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: November 1, 2022
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Steven Brunette, Jianwen Cui, Michael D. Lowe, Christopher Ronald Sarko, Simon Surprenant, Michael Robert Turner, Xinyuan Wu, Lana Louise Smith Keenan, Thierry Bouyssou, Paul Nicklin
  • Patent number: 11478451
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 25, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Katrin Nowak-Reppel, Chris Lemke, Michael H. Serrano-Wu, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren, Rebecca Ann Harvey, Daniel Payne, Thomas Pesnot, Craig Wilson
  • Patent number: 11479533
    Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 25, 2022
    Assignee: Kadmon Corporation, LLC
    Inventors: Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
  • Patent number: 11472772
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: October 18, 2022
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
  • Patent number: 11472962
    Abstract: An object of the present invention is to provide a compound exhibiting a cyan color having properties such as high chroma, high light fastness, and high solubility. The compound is represented by the following General Formula (1). In Formula (1), R1 and R2 each independently represent a linear, branched, or cyclic alkyl group having 6 or more and 12 or fewer carbon atoms, R3 represents a 4-alkylphenyl group, a 4-halogenated phenyl group, or a 3-alkoxyphenyl group, R4 represents a linear, branched, or cyclic alkyl group having 1 or more and 8 or fewer carbon atoms, and R5 represents a linear, branched, or cyclic alkyl group having 1 or more and 8 or fewer carbon atoms or a benzyl group.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: October 18, 2022
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Koromo Shirota, Ai Hayakawa, Tsuyoshi Santo
  • Patent number: 11466003
    Abstract: Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or preventing various diseases mediated by ALK5.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 11, 2022
    Assignee: SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
    Inventors: Zusheng Xu, Yangtong Lou, Li Chen
  • Patent number: 11453663
    Abstract: Compounds represented by the structural formula (1) where R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: September 27, 2022
    Assignee: MASARYKOVA UNIVERZITA
    Inventors: Kamil Paruch, Benoit Carbain, Stepan Havel, Vit Vsiansky, Fedor Nikulenkov, Lumir Krejci
  • Patent number: 11453681
    Abstract: The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: September 27, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Kristyna M. Elbel, Rao V. Kalla, Samuel E. Metobo, Scott A. Mitchell, Thao D. Perry, Scott P. Simonovich, Christopher A. Ziebenhaus
  • Patent number: 11447469
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 20, 2022
    Assignees: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Patent number: 11447482
    Abstract: Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-2? and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-2? or iron metabolism.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 20, 2022
    Assignee: KUDA THERAPEUTICS, INC.
    Inventors: Xiaohui Liu, Mei Yee Koh
  • Patent number: 11447490
    Abstract: Provided in the present application are an aromatic heterocyclic substituted olefin compound, a preparation method for same, a pharmaceutical composition of same, and applications thereof. The aromatic heterocyclic substituted olefin compound of the present invention is a novel ALK5 inhibitor and is for use in treating and/or preventing various ALK5-mediated diseases.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: September 20, 2022
    Assignee: SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
    Inventors: Zusheng Xu, Yangtong Lou, Li Chen, Kun Zeng, Qingrui Sun, Xiaoli Lei
  • Patent number: 11447504
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 20, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Katrin Nowak-Reppel, Jérémie Xavier Mortier, Patrick R. McCarren, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Laura Furst, Guo Wei, Rebecca Ann Harvey, Daniel Payne, Thomas Pesnot, Craig Wilson
  • Patent number: 11440923
    Abstract: The present invention relates to substituted macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 13, 2022
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning, Katrin Nowak-Reppel, Sven Wittrock, David McKinney, Michael H. Serrano-Wu, Chris Lemke, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Laura Furst, Guo Wei, Patrick R. McCarren, Rebecca Ann Harvey